文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经气管插管拔管后序贯经鼻高流量氧疗的初步评价

[Preliminary evaluation of sequential therapy by high flow nasal cannula oxygen therapy following endotracheal tube extubation in mechanically ventilated patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论与无创正压通气相比,拔管后序贯经鼻高流量氧疗可改善氧合、降低痰液黏稠度和鼻面部压疮发生率。

该前瞻性随机对照试验纳入2016年1月1日至12月31日上海市第十人民医院重症医学科49例气管插管拔管后序贯治疗患者,随机分为经鼻高流量氧疗组(HFNC组,n=25)和无创正压通气组(NPPV组,n=24)。结果显示,HFNC组各时间点痰液黏稠度均显著低于NPPV组(均P<0.01),12、24、48小时动脉血氧饱和度(SaO2)和动脉血氧分压(PaO2)均显著高于NPPV组(均P<0.05),而各时间点动脉血二氧化碳分压(PaCO2)差异无统计学意义。NPPV组发现4例鼻面部压疮(均为I期),HFNC组无鼻面部压疮(χ²=4.400,P=0.036)。ROC曲线分析显示HFNC改善氧合的AUC高于NPPV(0.917 vs. 0.830)。作者认为HFNC作为拔管后序贯治疗可行,可能值得在此类临床情境中广泛推荐。

要点

  • 拔管后序贯HFNC组12、24、48小时痰液黏稠度均显著低于NPPV组(均P<0.01),HFNC组多为稀薄痰(各时间点分别为15、16、15例)。
  • HFNC组12、24、48小时SaO2和PaO2均显著高于NPPV组(均P<0.05),两组各时间点PaCO2差异无统计学意义。
  • NPPV组4例出现鼻面部压疮(均为I期),HFNC组无鼻面部压疮(χ²=4.400,P=0.036)。
  • ROC曲线分析显示HFNC改善氧合的AUC为0.917,高于NPPV的0.830;HFNC治疗48小时PaO2为76.25 mmHg时,敏感度100%、特异度75.0%。
  • 作者认为HFNC作为机械通气患者拔管后序贯治疗可行,可能值得在此类临床情境中广泛推荐。

适用人群与场景

  • 上海市第十人民医院重症医学科2016年1月1日至12月31日收治的气管插管拔管后序贯治疗患者。

诊断标准与关键阈值

  • 氧疗良好效果定义为序贯治疗后48小时PaO2较治疗前升高20%。

处置流程与药物剂量

  • HFNC组给予加热湿化经鼻高流量氧疗,NPPV组给予无创正压通气,均为拔管后序贯治疗。
  • 于NPPV或HFNC治疗后12、24、48小时评估动脉血气及痰液黏稠度,并记录1周内鼻面部压疮。

研究设计与关键结果

  • 前瞻性随机对照试验,纳入49例拔管后序贯治疗患者,随机分为HFNC组(n=25)和NPPV组(n=24);HFNC组排除再插管1例和改为NPPV 2例,NPPV组排除放弃治疗1例和再插管1例,最终两组各22例完整数据。
  • HFNC组12、24、48小时痰液黏稠度均显著低于NPPV组(均P<0.01);NPPV组多为中度黏稠痰(各时间点分别为12、12、10例),HFNC组多为稀薄痰(各时间点分别为15、16、15例)。
  • HFNC组12、24、48小时SaO2均显著高于NPPV组:12小时0.978±0.009 vs. 0.906±0.139,24小时0.976±0.019 vs. 0.924±0.103,48小时0.973±0.019 vs. 0.935±0.079(均P<0.05)。
  • HFNC组12、24、48小时PaO2均显著高于NPPV组:12小时97.85±22.99 mmHg vs. 79.24±25.86 mmHg,24小时108.10±43.87 mmHg vs. 84.44±29.24 mmHg,48小时102.31±39.02 mmHg vs. 79.04±27.46 mmHg(均P<0.05)。
  • 两组各时间点PaCO2差异无统计学意义。
  • NPPV组4例出现鼻面部压疮(均为I期),HFNC组无鼻面部压疮,HFNC组较NPPV组显著减少(χ²=4.400,P=0.036)。
  • ROC曲线分析显示HFNC改善氧合的AUC为0.917,高于NPPV的0.830;HFNC治疗48小时PaO2为76.25 mmHg时,敏感度100%、特异度75.0%。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与NPPV相比,采用HFNC作为机械通气患者气管插管拔管后序贯治疗是可行方式,可改善氧合、降低痰液黏稠度和鼻面部压疮发生率。
  • 作者认为HFNC是有前景的治疗,可能值得在此类临床情境中广泛推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the feasibility and effect of sequential treatment by the heated humidified high flow nasal cannula oxygen therapy (HFNC) in mechanically ventilated patients following endotracheal tube extubation.

METHODS: A prospective randomized controlled trial was conducted. Forty-nine patients with the sequential treatment after tracheal intubation extraction admitted to Department of Critical Care Medicine of Shanghai Tenth People's Hospital from January 1st to December 31st 2016 were enrolled. The patients were randomly divided into HFNC group (n = 25) and non-invasive positive pressure ventilation (NPPV) group (n = 24) in accordance with the random number table. During the study, arterial blood gas and the sputum viscosity were assessed at 12, 24, and 48 hours after NPPV or HFNC treatment, and the nasal and facial pressure ulcers within 1 week was also recorded. Receiver operating characteristic curve (ROC) was plotted, and the effect of NPPV or HFNC on oxygenation was analyzed.

RESULTS: Among the 25 patients in the HFNC group, 1 patient who was re-intubated and 2 patients who were changed to NPPV were excluded, and a total of 22 patients with complete data were enrolled in HFNC group. Among the 24 patients in the NPPV group, 1 patient who gave up the treatment and 1 patient who was re-intubated were excluded, and a total of 22 patients with complete data were enrolled in NPPV group. After the sequential treatment, most patients in NPPV group showed moderate viscous sputum (12, 12 and 10 cases at 12, 24 and 48 hours, respectively), whereas the patients in HFNC group showed thin sputum (15, 16 and 15 cases at 12, 24 and 48 hours, respectively). Sputum viscosity of patients in HFNC group at each time point was significantly lower than that in NPPV group (all P < 0.01). Arterial oxygen saturation (SaO2) and arterial partial pressure of oxygen (PaO2) at 12, 24 and 48 hours in the HFNC group were significantly higher than those in the NPPV group [SaO2: 0.978±0.009 vs. 0.906±0.139 at 12 hours, 0.976±0.019 vs. 0.924±0.103 at 24 hours, 0.973±0.019 vs. 0.935±0.079 at 48 hours; PaO2 (mmHg, 1 mmHg = 0.133 kPa): 97.85±22.99 vs. 79.24±25.86 at 12 hours, 108.10±43.87 vs. 84.44±29.24 at 24 hours, 102.31±39.02 vs. 79.04±27.46 at 48 hours, all P < 0.05], however, the difference in arterial partial pressure of carbon dioxide (PaCO2) at all of the time points between the two groups was not significant. In NPPV group, 4 patients with nasal and facial pressure ulcers was found, and all with I phase of pressure ulcers, and no nasal and facial pressure ulcers was found in HFNC group, which was significantly decreased as compared with NPPV group (χ 2 = 4.400, P = 0.036). A good effect of oxygen therapy was defined as PaO2 at 48 hours after the sequential treatment was increased by 20% as compared with that before the treatment. ROC curve analysis showed that the area under the ROC curve (AUC) of HFNC on improving oxygenation was higher than that of NPPV (0.917 vs. 0.830); when PaO2 at 48 hours after HFNC treatment was 76.25 mmHg, the sensitivity was 100%, and the specificity was 75.0%.

CONCLUSIONS: Compared with NPPV, adoption of HFNC as sequential treatment is a feasible manner in dealing with the mechanically ventilated patients after endotracheal tube extubation, which can improve the oxygenation as well as reducing the degree of sputum viscosity and incidence of nasal and facial pressure ulcers. HFNC is a promising therapy, which may be worthy to recommend broadly in such a clinical situation.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhu Z, Liu Y, Wang Q, et al. [Preliminary evaluation of sequential therapy by high flow nasal cannula oxygen therapy following endotracheal tube extubation in mechanically ventilated patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28936951. doi:10.3760/cma.j.issn.2095-4352.2017.09.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。